Welcome to our dedicated page for Petros Pharmaceuticals news (Ticker: PTPI), a resource for investors and traders seeking the latest updates and insights on Petros Pharmaceuticals stock.
News about Petros Pharmaceuticals, Inc. (PTPI) centers on its efforts to build a technology-driven platform for prescription-to-over-the-counter (Rx-to-OTC) drug switches and its evolving capital markets profile. Company press releases describe Petros’ transition toward a smart healthcare technology model, highlighting development of a proprietary SaaS platform and Software-as-a-Medical-Device (SaMD) web application designed to help pharmaceutical sponsors navigate FDA requirements for nonprescription access.
Readers following PTPI news will see updates on the company’s AI- and big data–enabled platform, including collaborations with a big data and analytics provider and with Innolitics, which Petros identifies as a SaMD developer. These stories discuss enhancements such as identity verification, document authentication, deep fake detection, facial and ID recognition, and machine learning–based auto capture, all intended to support safe and appropriate OTC access to formerly prescription products.
Petros’ news flow also includes regulatory and policy context, with management statements about alignment with FDA’s "Nonprescription Drug Product with an Additional Condition for Nonprescription Use" (ACNU) rules and U.S. executive orders aimed at expanding OTC access and lowering drug prices. The company frequently references the emerging self-care market and its belief that its technology-assisted platform could help pharmaceutical partners pursue Rx-to-OTC switches across multiple indications.
In addition, PTPI news covers corporate and capital markets developments such as a reverse stock split, public offerings of common stock and warrants, and changes in listing status, including suspension and delisting from Nasdaq and transition to OTC trading. Coverage also addresses the deconsolidation and discontinued operations of Metuchen Pharmaceuticals and its subsidiaries, which Petros presents as part of a broader corporate realignment and balance sheet strengthening effort. Investors and observers can use this news stream to track Petros’ technology milestones, regulatory positioning, and key corporate actions over time.
Petros Pharmaceuticals, a leader in men's health therapeutics, announced that President Fady Boctor will present a corporate overview at the Q1 Investor Summit Conference on March 9, 2022, at 2:00 PM ET. This virtual event will allow attendees to learn about the company’s initiatives in addressing men's health issues, including erectile dysfunction and Peyronie's disease. Boctor will also be available for one-on-one meetings throughout the conference. Interested parties can register for the summit online.
For more information, visit their registration page.
Petros Pharmaceuticals (Nasdaq: PTPI) announced a collaboration with Dr. Drew Pinsky to enhance awareness and dialogue around erectile dysfunction (ED) and men's sexual health issues. Dr. Drew will leverage his substantial social media presence to promote Petros's treatments, including STENDRA® (avanafil) and potential therapies for Peyronie's disease. Despite the prevalence of ED affecting over 30 million men in the U.S., about 75% remain untreated. This partnership aims to destigmatize these conditions and encourage discussions around men's health.
Petros Pharmaceuticals (Nasdaq: PTPI) has announced a partnership with a leading Contract Development and Manufacturing Organization (CDMO) for the domestic production of STENDRA (avanafil) tablets. This partnership replaces the previous agreement with Vivus and aims to enhance the supply chain while reducing costs and increasing gross margins. The transition to U.S. manufacturing is expected to strengthen profitability and operational efficiencies. STENDRA is an oral PDE5 inhibitor used to treat erectile dysfunction, currently covered for approximately 75% of commercially insured lives.
Petros Pharmaceuticals (Nasdaq: PTPI) has initiated two self-selection studies for its erectile dysfunction medication STENDRA® (avanafil). These studies aim to gather data to support the drug's potential transition to over-the-counter (OTC) status. Following positive topline pivotal label comprehension results, these studies will assess consumer understanding of STENDRA® through draft OTC labeling. The outcomes will be shared with the FDA to enhance the OTC development plan. Currently, only about 25% of the 30 million men with erectile dysfunction in the U.S. are receiving oral therapy.
Petros Pharmaceuticals (Nasdaq: PTPI) has successfully closed a registered direct offering and private placement, raising approximately $7.5 million. The funds will support the expansion of its men's health platform and provide working capital. This capital boost marks the company's strongest cash position to date, enhancing their strategic plans in the men's health category. Katalyst Securities LLC acted as the financial advisor for this transaction. Petros aims to lead the market by developing innovative therapeutics for issues such as erectile dysfunction and Peyronie's disease.
Petros Pharmaceuticals, a leader in men's health therapeutics, has announced a definitive agreement for the sale of 2,186,589 shares at $3.43 per share, aiming to raise approximately $7.5 million. This includes a registered direct offering and a private placement. The proceeds will support the expansion of its men's health platform and general corporate purposes. The offering is expected to close around December 27, 2021. Unregistered shares and warrants were also included, with the company agreeing to register them within 15 days.
Petros Pharmaceuticals (Nasdaq: PTPI) reported positive results from its over-the-counter (OTC) draft label comprehension study for STENDRA® (avanafil), an erectile dysfunction drug. Conducted with 453 participants, including those with low health literacy, the study assessed understanding of key label messages. The favorable results support Petros's plans to seek FDA approval for OTC access to STENDRA, potentially the first of its kind in the U.S. This step aims to enhance accessibility for the estimated 30 million men suffering from erectile dysfunction, of which only about 25% currently receive therapy.
Petros Pharmaceuticals (Nasdaq: PTPI) has successfully closed a registered direct offering and private placement, raising approximately $10 million from its largest investor and other existing investors. The company will use the funds to expand its men's health platform, working capital, and general corporate purposes. CEO Fady Boctor stated that this additional funding strengthens their position as they aim to enhance the availability of STENDRA and grow their men's health portfolio. The firm is focused on being a leading provider of therapeutics for men's health issues.
Petros Pharmaceuticals, a leader in men's health therapeutics, will be presenting at the Benzinga Global Small Cap Conference on December 8, 2021. President and Chief Commercial Officer Fady Boctor is scheduled to deliver his presentation at 1:35 PM ET. Additionally, Mr. Boctor will be available for one-on-one meetings throughout the event, which runs from December 8 to 9. Petros focuses on addressing men's health issues, including erectile dysfunction and hormone health, by developing innovative therapeutic solutions.
Petros Pharmaceuticals (Nasdaq: PTPI) announced a definitive agreement to sell 3,333,333 shares of common stock at $3.00 per share, generating approximately $10 million in gross proceeds. The offering includes a registered direct offering of 2,153,333 shares and a private placement of 1,180,000 shares. Additionally, the company will issue warrants for 2,500,000 shares at an exercise price of $3.50. The funds will support the expansion of its men's health platform and general corporate purposes, with the transaction expected to close by December 2, 2021.
FAQ
What is the current stock price of Petros Pharmaceuticals (PTPI)?
What is the market cap of Petros Pharmaceuticals (PTPI)?
